{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-005590","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.064840+00:00","generated_at":"2026-06-24T00:19:59.226385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study","bullets":["Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.","Cash balance of $14.9M at quarter end; royalty payments from Takeda sublicensee ~$0.4M (+45% YoY).","In-licensed DNase-based oncology platform from CLS Therapeutics in April 2022; targeting Phase 1 in pancreatic carcinoma.","Engaged Catalent for cGMP manufacturing of Phase 1 clinical supply; collaboration with Belgian Volition for NETs-targeted cell therapies.","Bolstered IP with U.S. patent for XCART platform covering co-administration of CAR T cells with personalized vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-005590","json":"https://secwatch.observer/filing/0001683168-22-005590.json","markdown":"https://secwatch.observer/filing/0001683168-22-005590.md","text":"https://secwatch.observer/filing/0001683168-22-005590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/0001683168-22-005590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:19:59.226385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}